AMPK Inhibitor

AMPK Inhibitors (30):

Cat. No.	Product Name	Effect	Purity

HY-13418A

Dorsomorphin	Inhibitor	99.91%
Dorsomorphin (Compound C) is a selective and ATP-competitive AMPK inhibitor (K_i=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).

HY-13418

Dorsomorphin dihydrochloride	Inhibitor	99.91%
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a K_i of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).

HY-112083

BAY-3827	Inhibitor	99.66%
BAY-3827 is a potent and selective AMPK inhibitor with IC₅₀ values of 1.4 nM at low (10 μM ATP concentration) and 15 nM at high (2 mM ATP concentration). BAY-3827 shows over 500-fold selectivity for most of the 331 kinases. BAY-3827 prevents phosphorylation of acetyl-CoA carboxylase 1 and shows strongest anti-proliferative activity in androgen-dependent prostate cancer cell lines.

HY-151361

AMPK-IN-3	Inhibitor	98.51%
AMPK-IN-3 (compound 67) is a potent and selective AMPK inhibitor with IC₅₀s of 60.7, 107 and 3820 nM for AMPK (α2), AMPK (α1) and VEGFR2/KDR/Flk-1, respectively. AMPK-IN-3 inhibits AMPK does not affect cell viability or cause significant cytotoxicity in K562 cells. AMPK-IN-3 can be used in study of cancer.

HY-19805

STO-609	Inhibitor	98.13%
STO-609 is a selective and cell-permeable inhibitor of the Ca²⁺/calmodulin-dependent protein kinase kinase (CaM-KK), with K_i values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC₅₀ ~0.02 g/ml.

HY-153886

Wu-5	Inhibitor	99.34%
Wu-5 is a USP10 inhibitor that can inhibit FLT3 and AMPK pathways, induce FLT3-ITD degradation and induce apoptosis.

HY-15142R

Doxorubicin hydrochloride (Standard)	Inhibitor
Doxorubicin (hydrochloride) (Standard) is the analytical standard of Doxorubicin (hydrochloride). This product is intended for research and analytical applications. Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy.

HY-N0404

Sinigrin	Inhibitor	99.97%
Sinigrin is a major glucosinolate present in plants of the Brassicaceae family. Sinigrin inhibits early-stage adipogenesis of 3T3-L1 adipocytes through the AMPK and MAPK signaling pathways. Sinigrin has potent anti-oxidant, anti-tumor and anti-inflammatory effects.

HY-114317

MARK4 inhibitor 1	Inhibitor	98.29%
MARK4 inhibitor 1 is a potent and selective microtubule affinity-regulating kinase 4 (MARK4) inhibitor, with an IC₅₀ of 1.54 μM. MARK4 inhibitor 1 inhibits cancer cell proliferation, metastasis and induces apoptosis.

HY-112266

MARK-IN-4	Inhibitor	98.99%
MARK-IN-4 is a potent microtubule affinity regulating kinase (MARK) inhibitor with an IC₅₀ of 1 nM. Inhibition of microtubule affinity regulating kinase (MARK) represents a potentially attractive means of arresting neurofibrillary tangle pathology in Alzheimer's disease.

HY-D1163

Chromium(III) acetate	Inhibitor	≥99.0%
Chromium(III) acetate (Chromic acetate) is an AMPK inhibitor that promotes lipogenesis by inhibiting AMPK phosphorylation. Chromium(III) acetate has low toxicity in mammals, with an LD₅₀ of 2365 mg/kg in rats.

HY-101934

MARK-IN-2	Inhibitor	99.19%
MARK-IN-2 is a potent microtubule affinity regulating kinase (MARK) inhibitor with an IC₅₀ of 5 nM.

HY-156397

HTH-02-006	Inhibitor	99.49%
HTH-02-006 is a NUAK2 inhibitor (IC₅₀?=?126?nM). HTH-02-006 reduces levels of phosphorylated MYPT1 in HuCCT-1 cells. HTH-02-006 inhibits YAP-driven cell proliferation, hepatomegaly and tumorigenesis. HTH-02-006 also has antifibrotic protective effect.

HY-111588

Xanthoangelol	Inhibitor	99.65%
Xanthoangelol, extracted from Angelica keiskei, suppresses obesity-induced inflammatory responses. Xanthoangelol possesses antibacterial activity. Xanthoangelol inhibits monoamine oxidases. Xanthoangelol induces apoptosis in neuroblastoma and leukemia cells.

HY-101933

MARK-IN-1	Inhibitor	98.48%
MARK-IN-1 is a potent microtubule affinity regulating kinase (MARK) inhibitor with an IC₅₀ of <0.25 nM.

HY-153797

Dox-btn2	Inhibitor
Dox-btn2 is a biotinylated derivative of Doxorubicin (HY-15142A), with a biotin label at the point of conjugation to doxorubicin at 3'-NH₂. Dox-btn2 can be used for cell imaging. While Doxorubicin is mainly accumulated in the nucleus, while Dox-btn2 is mainly located in the cytoplasm.

HY-155943

AMPK-IN-4	Inhibitor
AMPK-IN-4 (compound 19) is a potent inhibitor of (AMPK(α1) and AMPK(α2) with IC₅₀s of 393 nM and 141 nM, respectively. AMPK-IN-4 plays an important role in cancer research.

HY-161440

SIK-IN-1	Inhibitor	98.12%
SIK-IN-1 (Compound 53) is an inhibitor for salt-inducible kinase (SIK), which inhibits SKI1, SIK2 and SIK3 with IC₅₀s of 0.1, 0.4 and 1.5 nM, respectively. SIK-IN-1 inhibits the release of TNFa with IC₅₀ of 0.5 nM, stimulates the LPS (HY-D1056) -induced IL-10 release with EC₅₀ of 4 nM in human macrophages.

HY-N6794

10Z-Hymenialdisine	Inhibitor
10Z-Hymenialdisine ((Z)-Hymenialdisine) is a natural bioactive pyrrole alkaloid. 10Z-Hymenialdisine is a pan kinase inhibitor, and has anticancer activities.

HY-12357S2

Bempedoic acid-d₄	Inhibitor	≥98.0%
Bempedoic acid-d₄ is the deuterium labeled Bempedoic acid. Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor. Bempedoic acid (ETC-1002) activates AMPK[1][2].

Name
Email *

	Sorry, but the email address you supplied was invalid.